IL3 and CD4+/CD56+ hematodermic neoplasm: An example of a member of this group is Tagraxofusp ElzonrisTM, an interleukin-3 (IL-3) with a payload of a truncated diphtheria toxin used to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients [12].